 MALVERN, Pa., April 29, 2022 GLOBE NEWSWIRE -- Ocugen, Inc. NASDAQ: OCGN, a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the companys research into the development of a modifier gene therapy to treat dry age-related macular degeneration AMD, and a novel biologic to treat wet-AMD and diabetic macular edema DME at The Association for Research in Vision and Ophthalmologys ARVO 2022 Annual Meeting in Denver on May 1 - 4, 2022. 